Background/Aims: Proteinuria in idiopathic minimal lesion nephrotic syndrome (IMLNS) is presumed to be due to the effect of circulating factors on glomerular permeability to plasma proteins. This study examines the expression of messenger ribonucleic acid (mRNA) for cytokines thought to mediate glomerular inflammation during different stages of the nephrotic syndrome. Methods: Messenger RNA expression and stability from peripheral blood mononuclear cells of IMLNS patients in relapse and in remission, and age matched normal controls were measured using a ribonuclease protection assay (RPA). The spontaneous and Interleukin 2 (IL-2) stimulated mRNA expression were studied. Results: Spontaneous mRNA expression for Interleukin 8 (IL-8) from IMLNS patients in relapse was significantly increased when compared to IMLNS patients in remission and normal controls (p < 0.05). After 14 h of IL-2 stimulation, mRNA IL-8 levels expressed by IMLNS PBMC patients in remission were not different from those observed in normal controls. However, after 5 days of PBMC incubation, a significant increase in mRNA for IL-8 in IMLNS patients compared to controls was found (p < 0.01). Stability assay demonstrated that IL-8 mRNA transcript from the nephrotic patients remained higher than those from controls and showed a significantly prolonged life t1/2 (p = 0.02). Conclusions: IL-8 mRNA expression is increased in IMLNS patients in relapse. Moreover, stability studies show that IL-8 mRNA life t1/2 is prolonged due to altered post-transcriptional regulation. This finding may explain the elevated serum IL-8 levels observed in these patients during relapse and may have pathogenic significance since IL-8 has been shown to induce proteinuria in the experimental animal.

Keywords:
Interleukin 8, Ribonuclease protection assay, Nephrotic syndrome
1.
Mallick NP: The pathogenesis of minimal change nephropathy. Clin Nephrol 1977;7:87–95.
2.
Abboud HE: Growth factors in glomerulonephritis. Kidney Int 1993;43:252–267.
3.
Schreiner GF: The role of the macrophage in glomerular injury. Semin Nephrol 1991;11:268–275.
4.
Abbott F, Ryan JJ, Ceska M, Matsushima K, Sarraf CE, Rees AJ: Interleukin 1-β stimulates human mesangial cells to sinthesize and release interleukins-6 and -8. Kidney Int 1991;40:597–605.
5.
Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor β and proteoglycan production in experimental glomerulonephritis. Possible role in the expansion of the mesangial extracellular matrix J Clin Invest 1990;86:453–462.
6.
Johnson R, Iida H, Yoshimura A, Floege J, Bowen-Pope DF: Platelet-derived growth factor: A potentially important cytokine in glomerular disease. Kidney Int 1992;41:590–594.
7.
Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Supression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990;346:371–374.
8.
Wada T, Tomosugi N, Naito T, Yokoyama H, Kobayashi K, Harada A, Mukaida N, Matsushima K: Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis. J Exp Med 1994;180:1135–1140.
9.
Garin EH, Blanchard K, Matsushima K, Djeu JY: IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int 1994;45:1311–1317.
10.
Neuhaus TJ, Wadhwa M, Callard R, Barratt TM. Increased IL-2, IL-4 and interferon-gamma (IFN-γ) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 1985;100:475–479.
11.
Bustos C, Gonzalez E, Muley R, Alonso JL, Egido J: Increase of tumour necrosis factor-α synthesis and gene expresion in peripheral blood mononuclear cells in children with idiopathic nephrotic syndrome. Europ J Clin Invest 1994;24:799–805.
12.
Daniel V, Trautman Y, Konrad M, Nayir A, Scharer K: T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol 1997;47:289–297.
13.
Wada T, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Naito T, Kobayashi K, Naofumi M, Matsushima K: Detection of urinary interleukin-8 in glomerular disease. Kidney Int 1994;46:455–460.
14.
Suranyi MG, Guasch A, Hall BM, Myers BD: Elevated levels of tumor necrosis factor-α in the nephrotic syndrome in humans. Am J Kidney Dis 1993;21:251–259.
15.
Churg J, Habib R, White RHR: Pathology of the nephrotic syndrome in children: A report for the International Study of Kidney Disease in Children. Lancet 1970;i:1299–1302.
16.
De Kant E, Rochlitz CF, Herrmann R: Gene expression analysis by a competitive and differential PCR with antisense competitors. Biotechniques 1994;17:934–942.
17.
Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC. Th1 and Th2 cytokine mRNA profile in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999;10:529–537.
18.
Standiford TJ, Kunkel SL, Rolfe MW, Evanoff HL, Allen RM, Striter RM: Regulation of human alveolar macrophage- and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol 1992;6:75–81.
19.
Yu Y, Chadee K: Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a post-transcriptional mechanism. J Immunol 1998;161:3746–3752.
20.
Bosco MC, Gusella GL, Espinoza-Delgado I, Longo DL, Varesio L: Interferon-γ regulates interleukin 8 gene expression in human monocytic cells by a posttranscriptional mechanism. Blood 1994;83:537–542.
21.
Stoeckle MY: Post-transcriptional regulation of froα,β,γ and IL-8 mRNAs by IL-1β. Nucl Acids Res 1991;19:917–920.
22.
MacDonald NE, Wolfish N, McLaine P, Phipps P, Rossier E: Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 1986;108:378–382.
23.
Mistchenko AS, Diez RA, Mariani AL, Robaldo J, Maffey AF, Bayley-Bustamante G, Grinstein S: Cytokines in adenovirus disease in children: Association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome. J Pediatr 1994;124:714–719.
24.
Garin EH, West L, Wang Z: Effect of interleukin 8 on glomerular sulfated compounds and albuminuria. Pediatr Nephrol 1997;11:274–279.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.